Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: ...

Third quarter 2021 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session. The third quarter of 2021 marked an ...

EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...

Parfois, l’innovation technologique peut provenir d’espace inattendus. Dans le développement de médicaments, cela signifie souvent l’intersection de technologies apparemment sans rapport ou de ...

Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Les résultats du troisième trimestre 2024 seront commentés par le management au cours d'un webcast audio en direct avec la communauté financière. La présentation sera suivie d'une session de questions ...

Bien que le phénomène de l’aggravation associée à l’inflammation neuroinflammatoire dans la sclérose en plaques soit largement reconnu par la communauté médicale, il reste encore beaucoup à faire pour ...